ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / VSTM / news
AMPH (72) RAPP (30) SNDX (17) SLN (44) ⌘ Pro Terminal →

Why VSTM Stock slipped -1.64% Today — RQD Quant Desk Flash

$9.59 -1.64% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $9.54

Verastem Inc. (VSTM) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $1.18B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on VSTM Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is VSTM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Verastem Inc. (NASDAQ: VSTM) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $9.59 (-1.64% 1D, market cap $1.18B). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 16/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, VSTM ranks #561 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does VSTM compare to AMPH and RAPP in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VSTM carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, AMPH (Amphastar Pharmaceuticals Inc.) holds a B grade (72/100 RQD, P/E 11.7x, ROIC 9.0%, cap $1.18B) and RAPP (Rapport Therapeutics Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -22.9%, cap $1.20B). Among the 5-stock peer group, AMPH leads on earnings multiple (11.7x) while AMPH leads on capital efficiency (9.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for VSTM?
▼

Per VSTM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001526119), Verastem Inc. generated $30.9M in revenue (+209.1% YoY), -$209.5M in net income, and -$137.5M in free cash flow against $246.4M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $9.54 (-0.49%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510036
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D- · Rk E
Cash (4)Whales (16)SEC (5)Macro (8)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-9.9% Base Target
$11 Bull$9 Base$7 Bear
📬 FREE VSTM RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for VSTM)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (36/100 Composite)
🔍 WHY VSTM SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+16/20 pts (44% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (22% of score)

FRED Regime × Technicals: 83% of 52W Range • RSI-14 at 61.2 (BULLISH MOMENTUM)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
28
Grade E$7.45+25.4% Next Q
Q2 (-2Q)
31
Grade E$9.34+8.1% Next Q
Q3 (-1Q)
33
Grade E$10.10-5% Next Q
Current
36
Grade D-$9.59-8.3% Hist 90D α
Trajectory: E (28) → D- (36)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a VSTM Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While VSTM currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Big institutional funds and options desks are actively positioning on the bullish side.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($8.27) and Max Pain ($10.07) forces dealer call-delta covering toward $11.36.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $VSTM• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “VSTM Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 36%NO 64%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why VSTM Stock slipped -1.64% Today — RQD Quant Desk Flash

Verastem Inc. (VSTM) slipped -1.64% to $9.59, trading at 83% of its 52-week range ($3.43 – $10.82). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 83% of its 52-week range ($3.43 – $10.82) with RSI-14 at 61.2 (BULLISH MOMENTUM).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $9.59 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live VSTM Headlines & Catalysts
RISK WATCHYahoo • 4d ago
Does Verastem (VSTM) Still Trade Near Fair Value On Sales?

Verastem has given shareholders a rough ride over the longer term, yet the share price has moved sharply enough at times to keep the story alive. With that backdrop, the live question is whether today's valuation can be

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring VSTM)

  • ✓Walkthrough of VSTM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
VSTM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +61.18%▲ ASCENDING CHANNEL
2026-11-03O $9.66H $9.75L $9.59C $9.59VOL 2.41M
RES: $10.39SUP: $7.01SMA50: $8.27SMA200: $6.20
$10.73$8.75$6.77$4.79$2.82RES $10.39SUP $7.01$9.592026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

VSTM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 VSTM Butterfly Map → + Track VSTM →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +209.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on VSTM today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for VSTM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for VSTM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (VSTM)

Health Care Rank #561 of 1015 ⚔️ AMPH vs VSTM Full Matrix →

1. Head-to-Head Health Care Peer Comparison (VSTM vs. AMPH, RAPP, SNDX, SLN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Verastem Inc. (VSTM) ranks #561 by composite RQD confidence (36/100, grade D-) and #334 by equity capitalization ($1.18B). Within this direct 5-issuer industry benchmark cohort, AMPH leads on earnings valuation at 11.7x trailing P/E, while AMPH leads on capital efficiency and profitability with 9.0% ROIC and 49.5% gross margin. AMPH currently holds the highest overall quantitative score in the immediate peer group at 72/100 (B) compared with VSTM at 36/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
VSTM ACTIVE
Verastem Inc.
D- 36/100 — — -35.0% -1.64% $1.18B Benchmark Subject
AMPH
Amphastar Pharmaceuticals Inc.
B 72/100 11.7x 49.5% 9.0% -2.49% $1.18B /amph-vs-vstm →
RAPP
Rapport Therapeutics Inc.
E 30/100 — — -22.9% +0.32% $1.20B /rapp-vs-vstm →
SNDX
Syndax Pharmaceuticals Inc.
E 17/100 — — -35.0% -4.03% $1.22B /sndx-vs-vstm →
SLN
Silence Therapeutics Plc American Depository Share
D 44/100 — 61.5% -35.0% +0.05% $1.23B /sln-vs-vstm →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001526119 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Verastem Inc. (VSTM) reported GAAP revenue of $30.9M (+209.1% vs. FY2024 revenue of $10.0M , and -88.0% cumulative change since FY2023) , GAAP net income of -$209.5M, operating cash flow of -$137.5M, and free cash flow of -$137.5M (-31.2% YoY). On the balance sheet, VSTM closed FY2025 with $246.4M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $30.9M -$209.5M -$137.5M -$137.5M $246.4M —
FY2024 (FY) 2024-12-31 $10.0M -$130.6M -$104.8M -$104.8M $101.5M —
FY2023 (FY) 2023-12-31 $257.8M -$87.4M -$86.5M -$86.5M — —

3. VSTM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is VSTM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Verastem Inc. (NASDAQ: VSTM) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $9.59 (-1.64% 1D, market cap $1.18B). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 16/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, VSTM ranks #561 in composite RQD confidence.

How does VSTM compare to AMPH and RAPP in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VSTM carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, AMPH (Amphastar Pharmaceuticals Inc.) holds a B grade (72/100 RQD, P/E 11.7x, ROIC 9.0%, cap $1.18B) and RAPP (Rapport Therapeutics Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -22.9%, cap $1.20B). Among the 5-stock peer group, AMPH leads on earnings multiple (11.7x) while AMPH leads on capital efficiency (9.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for VSTM?

Per VSTM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001526119), Verastem Inc. generated $30.9M in revenue (+209.1% YoY), -$209.5M in net income, and -$137.5M in free cash flow against $246.4M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is VSTM trading relative to its 50-day, 200-day, and 52-week technical levels?

VSTM last traded at $9.59 (-1.64% on volume of 2,112,810 shares), positioning the stock +15.96% above its 50-day simple moving average ($8.27) and +54.68% above its 200-day simple moving average ($6.20). Across its 52-week range of $3.43 to $10.82, VSTM sits at the 83.4% percentile with a 14-day RSI of 61.2 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($8.39 to $10.79).

Direct Sub-Reports: VSTM RQD Cockpit VSTM 12M Forecast VSTM Earnings & Move VSTM Dividends & DRIP VSTM Insiders & 13F VSTM Whale Options VSTM Profit Sankey VSTM News & Why
ROARABLE RATING BRIEF • RQD 36/100 (D-) ✓ SEC XBRL & RQD VERIFIED

VSTM — Verastem Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Verastem Inc. (VSTM) earns a live Roarable RQD composite score of 36/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $9.59 (-1.64% 1D, market capitalization $1.18B).

  • Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of -60.0%, and free cash flow yield of -11.72%.
  • Whale 13F & Options Flow (16/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (5/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Verastem Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry..2B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Verastem Inc. (VSTM) reported $30.9M in annual revenue (up from $10.0M in FY2024, +209.1% YoY) and -$209.5M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($257.8M revenue, -$87.4M net income) through FY2025, VSTM scaled operating cash flow to -$137.5M and free cash flow to -$137.5M, backed by $246.4M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 36/100): Big institutional funds and options desks are actively positioning on the bullish side. Free cash flow yield of -11.72% and institutional whale pillar of 16/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 16/20, sustained execution supports upside toward the upper end of the $3.43 – $10.82 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), VSTM carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can VSTM sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $30.9M and free cash flow of -$137.5M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is VSTM's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

VSTM Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Verastem Inc. (VSTM) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to VSTM Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

VSTM Bull vs. Bear Conversation Board — What's Your Call at $9.59?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON VSTM 🐻 33% BEARISH CONVICTION
1. Pick Your Side on VSTM:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $11.21 (+15.0%)
📌 Pinned Debate

Institutional accumulation and options positioning score 16/20 in the RQD rating, and analysts are cited as expecting upside after stro

Institutional accumulation and options positioning score 16/20 in the RQD rating, and analysts are cited as expecting upside after strong trial data.. When you look under the hood at VSTM, Fundamental Cash Engine is 4/20 with 0.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (16/20) has been quietly accumulating below $10.82. My 12M target is $11.21.

ArenaChamp_24 🐂 BULL

@SiliconVal_Bull Agree on the RQD 36/100 quality, though with 1.0 beta I'm scaling in with half-size at $9.75 and keeping dry powder in case we test $9.07.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $8.09 (-17.0%)
Spot @ $9.75

With an Altman Z of 0.2, Piotroski F of 3/9, FY 2025 net loss of -$209.5M, and a $250 Million equity offering, the balance sheet and ca

Careful chasing VSTM at $9.75. With an Altman Z of 0.2, Piotroski F of 3/9, FY 2025 net loss of -$209.5M, and a $250 Million equity offering, the balance sheet and cash burn are the dominant risks.. Gross margin is 0.0%, but operating margin is -60.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $8.09 on multiple compression.

LIVE TAPE